Free shipping on orders over $95Buy one with 1% offer on sale price
Zoom the image with the mouse
Drugs Affecting Lipid Metabolism: Risks Factors and Future Directions
ISBN:
9789401066259
List Price:
$54.99
Share:
Special Offers Available
Free shipping on orders over $95Buy one with 1% offer on sale priceBuy New
We can help you leverage the power of books
Customer Service
Connect with a dedicated account manager who is there every step of the way.
Price Match Guarantee
If you see better pricing elsewhere on your desired quantity, we will price match so you can be sure to get the best pricing.
Free Shipping
Enjoy free ground shipping on your order of $95 or more!
Brand New Guarantee
We only sell books that are brand new and protect that with a guarantee.
Customization
From author signatures to marketing inserts, custom packaging to brand stickers, we can help take your book marketing to the next level.
Details
Even a brief scan of the table of contents of the present volume is enough to disclose the diversity of research interests and opinions in the field of lipidology. It is precisely this diversity that is the strength of our field and that was showcased by the XII International Symposium of DRUGS AFFECTING LIPID METABOLISM (DALM). The papers published here from these proceedings may be divided into three categories: those that define-and refine---our understanding ofthe clinical benefit of aggressive lipid management, those that develop our knowledge of ris!. assessment, and those that discuss the genetic, bio~hemical, and biophysical mechanisms underlying the pathology of coronary heart disease. On the clinical front, further analysis of the results of the Scandinavian Simvastatin Survival Study (4S) has indicated the cost-effectiveness of therapy in patients with established coronary heart disease. The West of Scotland Coronary Prevention Study (WOSCOPS), whose methodology was described at the DALM XII symposium, has demonstrated in a mostly primary-prevention population what 4S demonstrated for secondary prevention the year before: aggressive lipid-regulating therapy reduces coronary heart disease morbidity and mortality rates without concurrently increasing mortality from noncardiovascular causes. In the future, important considerations will be to develop protocols that maximize benefit in groups underrepresented in traditional clinical research for example, women and the elderly-and to improve compliance to existing treatment regimens. Furthermore, antioxidant, omega-3 fatty acid, and gene therapies warrant further investigation.
Product details
Need Books? Bookpal makes it easy
Connect With Us
Customer Reviews
Products related to this item
Related Products